New Rhein Healthcare Investors announced has agreed to sell its 60 per cent stake in Softhale NV to Sino Biopharmaceutical Limited for a USD110 million upfront payment plus a profit share.
The total deal value could exceed USD200 million subject to Softhale’s business development. The sale of Softhale marks the first exit from New Rhein’s latest fund, which was launched in 2018.
Headquartered in Belgium, Softhale has developed a new generation of Soft Mist Inhalation (SMI) devices to improve respiratory treatments. The company delivers proven drugs through its proprietary SMI device designed to deliver medication to the lungs more effectively than other types of inhalers. The WHO estimates that 235 million people suffer from asthma, and four million die prematurely from chronic respiratory disease every year. Softhale’s products offer the potential to substantially improve the treatment paradigm for asthma and Chronic Obstructive Pulmonary Disorder (COPD) globally.
Source: Private Equity Wire
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.